Bristol Myers Squibb’s Zeposia has lost its exclusive status as the sole S1P receptor modulator available for ulcerative colitis treatment. The FDA has granted approval for Pfizer’s ulcerative colitis medication, Etrasimod, under the brand name Velsipity. This decision comes after the publication of Phase III results in The Lancet, the company announced on October 13.
Pfizer’s etrasimod has received FDA approval as a daily oral treatment for adults with moderate to severe active ulcerative colitis. Velsipity becomes the second sphingosine-1-phosphate (S1P) medication to enter the ulcerative colitis treatment market, following the FDA’s approval of Bristol Myers Squ...
